Tirzepatide denied as non-formulary by Aetna?

Aetna's specific coverage criteria for tirzepatide are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Aetna Denied Tirzepatide as Non-Formulary

A non-formulary denial means tirzepatide is not included on Aetna's current drug formulary for your specific plan, or it is placed on a tier that requires additional steps before the plan will cover it. Formulary decisions are made at the plan level and vary by employer group and plan year, so a drug covered under one Aetna plan may not be covered under another.

This denial is appealable through a formulary exception process, which exists precisely for situations where a non-formulary drug is medically necessary for a specific patient. Federal law and most state laws require plans to have a formulary exception process, and medically necessary cases that have failed or cannot use formulary alternatives are the standard basis for winning one.

## Your Appeal Rights

• Formulary exception request: This is usually the first step — a formal request that Aetna cover tirzepatide as if it were on formulary because no formulary alternative is clinically appropriate for you.
• ACA §2719 / ERISA §503: If the exception is denied, you have the right to a full internal appeal and then independent external review.
• Internal appeal deadline: Typically 180 days from the denial notice; confirm on your Explanation of Benefits.
• External review window: Approximately four months from the final internal denial to file for external review.
• Expedited option: Available when your health condition is urgent; request it explicitly in writing.

## Documentation to Gather

1. List of formulary alternatives: Obtain from Aetna (or your plan's formulary document) every drug on the formulary that Aetna considers a therapeutic alternative to tirzepatide. 2. Trial and failure or contraindication history: For each formulary alternative, document in your chart (with dates) that it was tried and failed to achieve adequate clinical response, was not tolerated, or is contraindicated based on your prescriber's clinical judgment. 3. Diagnosis confirmation and clinical severity: Current chart notes confirming your diagnosis and the severity of your condition, with objective clinical markers recorded by your provider. 4. Prescriber medical-necessity letter: Your prescriber should state specifically why each formulary alternative is inadequate or inappropriate for you and why tirzepatide is the medically necessary choice. 5. Insurer policy mapping: Review Aetna's formulary exception policy and any published clinical criteria. Address each requirement directly in your submission.

## Criteria-Mapping Structure

For a formulary exception, structure your documentation as: Formulary alternative drug | Date trialed | Duration | Clinical outcome or reason not appropriate | Chart reference. This table, attached to the prescriber's letter, makes the clinical case for exception in the clearest possible form for the reviewing pharmacist or physician.

Verify the current formulary tier status of tirzepatide under your specific Aetna plan (it changes annually during open enrollment) and review Aetna's formulary exception policy before submitting — the criteria for exception must be addressed exactly as written.